New drug cocktail aims to extend life in Tough-to-Treat colon cancer
NCT ID NCT03829462
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 3 trial tests whether combining regorafenib with irinotecan helps people with metastatic colorectal cancer live longer than regorafenib alone. The study includes 377 patients whose cancer has progressed after standard treatments. The goal is to see if the combination improves overall survival and disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34298, France
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre François Baclesse
Caen, Basse-Normandie, 14000, France
-
Centre Léon Bérard
Lyon, Rhône, 69008, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Pontchaillou
Rennes, Ile Et Vilaine, 35000, France
-
Hôpital Robert Debré
Reims, Marne, 51100, France
-
Hôpital Saint-Jean
Perpignan, Pyrénées-orientales, 66000, France
-
Hôpital privé Jean Mermoz
Lyon, Rhône, 69008, France
-
Institut Godinot
Reims, Marne, 51100, France
-
Institut Gustave Roussy
Villejuif, Val De Marne, 94800, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib and irinotecan
What this could lead to
If successful, this combination could offer a new treatment option for patients with metastatic colorectal cancer who have run out of standard therapies.
What could go wrong
This is a late-stage trial, but the drugs are already approved; the main question is whether the combination works better than regorafenib alone. Side effects from both drugs may be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.